Evidence map›Paper›PMID 26956207›Full record

ReviewStem cells translational medicine2016

Concise Review: Endothelial Progenitor Cells in Regenerative Medicine: Applications and Challenges.

Mark Seow Khoon Chong, Wei Kai Ng, Jerry Kok Yen Chan

Open access · goldAbstract readReview
In one paragraph

Review in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 193 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Dual ROS modulation by MnOTheranostics · 2026
    Article
  8. Isolation of endothelial progenitor cells from human adipose tissue.International journal of obesity (2005) · 2025
    Article
  9. Endothelial Progenitor Cells: Disease Markers and Potential Therapy in Kidney Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Endothelial Progenitor Cells: A Brief Update.International journal of stem cells · 2024
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mark Seow Khoon ChongSchool of Chemical and Biochemical Engineering, Nanyang Technological University, Singapore.
Wei Kai NgSchool of Chemical and Biochemical Engineering, Nanyang Technological University, Singapore.
Jerry Kok Yen ChanDepartment of Reproductive Medicine, KK Women's and Children's Hospital, Singapore Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore Department of Obstetrics and Gynaecology, National University of Singapore, Singapore jerrychan@nus.edu.sg.
Nanyang Technological University · SGKK Women's and Children's Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledEndothelial progenitor cells (EPCs) are currently being studied as candidate cell sources for revascularization strategies. Significant advances have been made in understanding the biology of EPCs, and preclinical studies have demonstrated the vasculogenic, angiogenic, and beneficial paracrine effects of transplanted EPCs in the treatment of ischemic diseases. Despite these promising results, widespread clinical acceptance of EPCs for clinical therapies remains hampered by several challenges. The present study provides a concise summary of the different EPC populations being studied for ischemic therapies and their known roles in the healing of ischemic tissues. The challenges and issues surrounding the use of EPCs and the current strategies being developed to improve the harvest efficiency and functionality of EPCs for application in regenerative medicine are discussed. SIGNIFICANCE: Endothelial progenitor cells (EPCs) have immense clinical value for cardiovascular therapies. The present study provides a concise description of the EPC subpopulations being evaluated for clinical applications. The current major lines of investigation involving preclinical and clinical evaluations of EPCs are discussed, and significant gaps limiting the translation of EPCs are highlighted. The present report could be useful for clinicians and clinical researchers with interests in ischemic therapy and for basic scientists working in the related fields of tissue engineering and regenerative medicine.

Indexed as

AnimalsEndothelial Progenitor CellsHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansNeovascularization, PhysiologicRegenerative MedicineStem Cell TransplantationClinical translationEndothelial cellHematopoietic cellsHematopoietic progenitorsStem/progenitor cellTissue regenerationTissue-specific stem cells

Identifiers

PMID26956207
PMCPMC4798740
OpenAlexW2302060297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.